Samsung Bioepis Announces Five-year Follow-up Results for ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2 Positive Breast Cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
12 sept. 2021 18h05 HE
|
Samsung Bioepis
Five-year follow-up results show comparable cardiac safety profile and long-term efficacy between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN® i (trastuzumab) in early or...
A Post-hoc Analysis of Phase 3 Study Demonstrates Baseline Factors Associated with Visual Acuity and Anatomical Outcomes of Samsung Bioepis’ BYOOVIZ™ (Ranibizumab) in nAMD at the EURETINA 2021
09 sept. 2021 06h00 HE
|
Samsung Bioepis
The post-hoc analysis shows that baseline age, best corrected visual acuity (BCVA), central subfield thickness (CST), and total lesion size were identified to be associated with the visual acuity and...
Samsung Bioepis Announces Analytical Similarity Data on SB11 (ranibizumab) at the ARVO Annual Meeting 2021
01 mai 2021 07h01 HE
|
Samsung Bioepis
Analytical assessment demonstrates structural, physicochemical, and biological similarity between SB11 and Lucentis SB11 is under review by the FDA and EMA INCHEON, Korea, May 01, 2021 (GLOBE...
Samsung Bioepis Continues Global Market Expansion with Launch of HADLIMA™ in Australia and Canada in partnership with Merck & Co.
29 mars 2021 05h30 HE
|
Samsung Bioepis
Samsung Bioepis broadens its global reach by launching HADLIMA™ in Australia and in Canada, both in partnership with Merck & Co.Samsung Bioepis’ adalimumab is now available in three markets:...
Samsung Bioepis Opens the New State-of-the-Art Headquarters to Accommodate Next Stage of Growth and Innovation
25 janv. 2021 06h00 HE
|
Samsung Bioepis
Located in Korea’s ‘Bio Cluster’ of Songdo in the Incheon Free Economic Zone (IFEZ) The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of...
Samsung Bioepis Announces First Real-World Data on RENFLEXIS® (infliximab-abda) with IBD patients from Veterans Affairs Healthcare System at the American College of Gastroenterology (ACG) 2020
26 oct. 2020 08h00 HE
|
Samsung Bioepis
Switching from reference infliximab or infliximab-dyyb to RENFLEXIS® (infliximab-abda) demonstrated comparable efficacy and safety in IBD patients registered to VA Healthcare SystemContinuation rates...
Samsung Bioepis Receives European Commission Approval for AYBINTIO® (Bevacizumab)
20 août 2020 04h47 HE
|
Samsung Bioepis
AYBINTIO® is approved for the treatment of the same types of cancer as reference bevacizumab (AVASTIN®i)AYBINTIO® is Samsung Bioepis’ fifth biosimilar to be approved by the European Commission ...
Samsung Bioepis Receives Positive CHMP Opinion for AYBINTIO® (Bevacizumab)
26 juin 2020 07h12 HE
|
Samsung Bioepis
AYBINTIO®, a biosimilar candidate referencing Avastin®i (bevacizumab), is Samsung Bioepis’ second oncology biosimilar to be recommended for marketing authorization by the European Medicines...